
PRESS: FDA Clearance of Investigational New Drug for Patients with Krabbe Disease
Forge Biologics has received IND, IBC, and IRB clearance for FBX-101, a gene therapy for patients with Krabbe disease, a...
Forge Biologics has received IND, IBC, and IRB clearance for FBX-101, a gene therapy for patients with Krabbe disease, a...
In the spirit of football season, we're introducing our very own roster of seasoned #genetherapy players. Our leadership team has...
Forge Biologics is a #genetherapy manufacturing and development company helping clients achieve their cGMP program goals. Forge enables AAV vector production at...
We recently celebrated a milestone by (literally) planting our flag at our HQ in Columbus, Ohio. This day celebrated many...
Forge Biologics Strengthens Gene Therapy Leadership with Key Hires in AAV Manufacturing, Regulatory Affairs and Finance to Support Strategic GrowthForge...
For rare disease families, time is the real enemy. Meet our Chief Medical Officer, Dr. Maria Escolar, and learn how...
Ohio-based startup Forge Biologics closed a $40 million Series A financing roundthat will be used to expand manufacturing capabilities and support...